This story was co-published with The Washington Post. Medicare’s prescription drug program spent nearly $4.6 billion in the first half of this year on expensive new cures for the liver disease hepatitis C — almost as much as it spent for all of 2014. Rebates from pharmaceutical companies — the amounts of which are confidential —…